Sign In
Buy AYTU
$2.23
+0.0800 (+3.72%)
At Close: Jul 31, 2026
Aytu BioPharma, Inc. (AYTU) Analyst/Investor Day Transcript
08:05pm, Tuesday, 20'th Jan 2026
Aytu BioPharma, Inc. (AYTU) Analyst/Investor Day Transcript
Aytu BioPharma Recaps Investor Day Held on January 20, 2026
04:05pm, Tuesday, 20'th Jan 2026
DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central n
Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
04:15pm, Tuesday, 13'th Jan 2026
DENVER, CO / ACCESS Newswire / January 13, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central n
Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City
08:00am, Monday, 12'th Jan 2026
DENVER, CO / ACCESS Newswire / January 12, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central n
Aytu BioPharma Inc. (NASDAQ:AYTU) Receives Consensus Recommendation of “Hold” from Brokerages
01:14am, Sunday, 28'th Dec 2025
Aytu BioPharma Inc. (NASDAQ: AYTU - Get Free Report) has been given a consensus recommendation of "Hold" by the five ratings firms that are presently covering the company, Marketbeat.com reports. One
Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City
09:00am, Thursday, 18'th Dec 2025
DENVER, CO / ACCESS Newswire / December 18, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central
EXXUA is now available through Aytu RxConnect® pharmacies to ensure optimal access and availability EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving
AWM Investment Company Inc. Takes $1.35 Million Position in Aytu BioPharma Inc. $AYTU
03:51am, Saturday, 13'th Dec 2025
AWM Investment Company Inc. purchased a new position in Aytu BioPharma Inc. (NASDAQ: AYTU) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange C
Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference
04:05pm, Monday, 24'th Nov 2025
DENVER, CO / ACCESS Newswire / November 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central
Aytu BioPharma, Inc. (AYTU) Q1 2026 Earnings Call Transcript
09:21pm, Thursday, 13'th Nov 2025
Aytu BioPharma, Inc. ( AYTU ) Q1 2026 Earnings Call November 13, 2025 4:30 PM EST Company Participants Joshua Disbrow - CEO & Director Ryan J. Selhorn - CFO, Corporate Secretary & Treasurer Conference
Aytu BioPharma Inc. (AYTU) Reports Q1 Loss, Tops Revenue Estimates
06:20pm, Thursday, 13'th Nov 2025
Aytu BioPharma Inc. (AYTU) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.2 per share a year ago.
Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results
04:05pm, Thursday, 13'th Nov 2025
Total net revenue of $13.9 million Net income of $2.0 million, or $0.21 net income per share basic Adjusted EBITDA1 of $(0.6) million, which includes EXXUA launch investments $32.6 million cash balanc
Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025
04:05pm, Wednesday, 05'th Nov 2025
DENVER, CO / ACCESS Newswire / November 5, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central n
Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)
09:00am, Tuesday, 28'th Oct 2025
DENVER, CO / ACCESS Newswire / October 28, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central n
New Strong Sell Stocks for Oct. 13th
09:46am, Monday, 13'th Oct 2025
AYTU, ALK and CNM have been added to the Zacks Rank #5 (Strong Sell) List on October 13, 2025.
